20 June 2023 - Initiating legal proceedings against medical spas, weight loss or wellness clinics, and compounding pharmacies to cease and desist from false advertising, trademark infringement and unlawful sales.

Novo Nordisk announced today that it is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and compounded semaglutide products claiming to contain semaglutide, while reinforcing the responsible use of Novo Nordisk's FDA approved medicines.

Read Novo Nordisk press release